Nutlin-3 induces HO-1 expression by activating JNK in a transcription-independent manner of p53

International Journal of Oncology
Yun-Jeong ChoeHo-Shik Kim

Abstract

A recent study reported that p53 can induce HO-1 by directly binding to the putative p53 responsive element in the HO-1 promoter. In this study, we report that nutlin-3, a small molecule antagonist of HDM2, induces the transcription of HO-1 in a transcription-independent manner of p53. Nutlin-3 induced HO-1 expression at the level of transcription in human cancer cells such as U2OS and RKO cells. This induction of HO-1 did not occur in SAOS cells in which p53 was mutated and was prevented by knocking down the p53 protein using p53 siRNA transfection, but not by PFT-α, an inhibitor of the transcriptional activity of p53. Accompanying HO-1 expression, nutlin-3 stimulated the accumulation of ROS and the phosphorylation of MAPKs such as JNK, p38 MAPK and ERK1/2. Nutlin-3-induced HO-1 expression was suppressed by TEMPO, a ROS scavenger, and chemical inhibitors of JNK and p38 MAPK but not ERK1/2. In addition, nutlin‑3-induced phosphorylation of JNK but not p38 MAPK was inhibited by TEMPO. Notably, the levels of nutlin-3-induced ROS were correlated with the mitochondrial translocation of p53 and this induction was prevented by PFT-μ, an inhibitor of the mitochondrial translocation of p53. Consistent with the effect of the ROS scavenge...Continue Reading

References

Apr 2, 2003·Molecular Cell·Motohiro MiharaUte M Moll
Jan 6, 2004·Science·Lyubomir T VassilevEmily A Liu
Mar 17, 2004·Molecular Cell·Haim Y CohenDavid A Sinclair
Apr 13, 2004·Nature Cell Biology·J I-Ju LeuDonna L George
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pascal O BerberatHelmut Friess
Sep 9, 2005·The Journal of Biological Chemistry·Frank EssmannReiner U Jänicke
Dec 20, 2005·Cell·Sophie JanssensJürg Tschopp
Jan 31, 2006·Proceedings of the National Academy of Sciences of the United States of America·Christian TovarLyubomir T Vassilev
Apr 8, 2006·Physiological Reviews·Stefan W RyterAugustine M K Choi
Sep 23, 2006·American Journal of Respiratory Cell and Molecular Biology·Jawed Alam, Julia L Cook
Nov 28, 2006·Trends in Molecular Medicine·Lyubomir T Vassilev
Jan 19, 2008·Blood·Stuart A Rushworth, David J MacEwan
Apr 24, 2008·Nature Reviews. Molecular Cell Biology·Todd RileyArnold Levine
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Sep 25, 2009·Nature Reviews. Cancer·Daniel MenendezMichael A Resnick
Aug 14, 2010·Current Drug Targets·Halina WasAlicja Jozkowicz
Oct 16, 2010·Seminars in Cancer Biology·Ju Dong YangLewis R Roberts
Jan 11, 2013·Nature Reviews. Cancer·Mark WadeGeoffrey M Wahl
Jan 15, 2013·International Journal of Oncology·Sun-Young LeeHo-Shik Kim

❮ Previous
Next ❯

Citations

May 29, 2014·International Journal of Oncology·Sun-Young LeeHo-Shik Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis